Raltegravir
Specifications
518048-05-0CAS Number
610-733-3EC Number
N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamideIUPAC Name
C20H21FN6O5Chemical Formula
444.4 g/molMolecular Weight
Raltegravir; 518048-05-0; MK-0518; MK0518; raltegravirum; DTXSID2048660; MK 0518; N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide; CHEBI:82960; 22VKV8053U; 4-Pyrimidinecarboxamide, N-((4-fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-; DTXCID5028586; L000900612; L-000900612; N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-; N-(2-(4-((4-fluorophenyl)methylcarbamoyl)-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; RefChem:55964; J05AX08; 0518, MK; Raltegravir (MK-0518); N-(2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; Raltegravir (INN); MFCD10698872; C20H21FN6O5; NCGC00184997-01; RALTEGRAVIR [INN]; N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide; Isentress(TM); N-[1-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxo-pyrimidin-2-yl]-1-methyl-ethyl]-5-methyl-1,3,4-oxadiazole-2-carboxamide; CAS-518048-05-0; Raltegravir [USAN:INN]; UNII-22VKV8053U; Raltegravir?; HSDB 8124; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di hydropyrimidine-4-carboxamide; RLT; 518048-05-0 (free); RALTEGRAVIR [MI]; Raltegravir(MK-0518); Raltegravir; MK-0518; Epitope ID:231726; K-0518; RALTEGRAVIR [VANDF]; RALTEGRAVIR [MART.]; hydropyrimidine-4-carboxamide; SCHEMBL51817; RALTEGRAVIR [WHO-DD]; MLS006011985; SCHEMBL996804; RALTEGRAVIR [EMA EPAR]; CHEMBL254316; orb1224836; orb1305950; SCHEMBL2112870; Raltegravir - Bio-X trade mark; BDBM25351; GTPL11571; CZFFBEXEKNGXKS-UHFFFAOYSA-N; GLXC-90212; HMS3655B09; HMS5080N13; EX-A2147; Tox21_113019; EBC-07544; NSC762522; s2005; T2239L; AKOS015902444; AKOS025149884; AKOS032960305; Tox21_113019_1; AC-5261; CCG-269170; DB06817; FR29048; NSC-762522; PB13312; SB20935; NCGC00274066-01; NCGC00274066-05; AS-16992; BR164312; HY-10353; SMR003601806; NS00015450; R0247; SW220138-1; D06676; EN300-120882; yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide; AB01566833_01; F547236; Q421552; BRD-K05658747-001-02-9; BRD-K05658747-001-03-7; BRD-K05658747-237-01-1; [(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-; N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-; Z1532717445; N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo -4-pyrimidinecarboxamide; N-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl) -5-methyl-1,3,4-oxadiazole-2- carboxamide; N-(2-(4-(4-FLUOROBENZYLCARBAMOYL)-5-HYDROXY-1-METHYL-6-OXO-1,6- DIHYDROPYRIMIDIN-2-YL)PROPAN-2-YL)-5-METHYL-1,3,4-OXADIAZOLE-2-CARBOXAMIDE; N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-OH-1-Me-6-oxo-pyrimidin-2-yl)propan-2-yl)-5-Me-1,3,4-oxadiazole-2-carboxamide; N-(4-FLUOROBENZYL)-5-HYDROXY-1-METHYL-2-(1-METHYL-1-(((5-METHYL-1,3,4-OXADIAZOL-2-YL)CARBONYL)AMINO)ETHYL)-6-OXO-1,6-DIHYDROPYRIMIDINE-4-CARBOXAMIDE; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; N-[(4-Fluorophenyl)methyl]-5-hydroxy-1-methyl-2-[2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide; N-[2-(4-{[(4-fluorophenyl)methyl]carbamoyl}-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamideSynonyms
Products Containing Raltegravir
ISENTRESS 600 MG COMPRIMIDOS RECUBIERTOS CON PELICULAISENTRESS 400 MG COMPRIMIDOS RECUBIERTOS CON PELICULAISENTRESS 25 MG COMPRIMIDOS MASTICABLESISENTRESS 100 MG COMPRIMIDOS MASTICABLESIsentressRaltegravir Tablets 400mgRaltegravirRaltegravirRALTEGRAVIR CAS 518048-05-0 INTERMEDIATESRaltegravirRaltegravirRALTEGRAVIR
